{"id":"W4206576793","doi":"10.1200/jco.2021.39.15_suppl.4080","title":"Lenvatinib plus pembrolizumab for patients with previously treated biliary tract cancers in the multicohort phase 2 LEAP-005 study.","year":2021,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cholangiocarcinoma and Gallbladder Cancer Studies","field":"Medicine","cited_by":27,"is_retracted":false,"has_abstract":true,"ca_institutions":"Health Sciences Centre; University of Toronto; Sunnybrook Health Science Centre","funders":"","keywords":"Lenvatinib; Medicine; Pembrolizumab; Internal medicine; Response Evaluation Criteria in Solid Tumors; Oncology; Clinical endpoint; Adverse effect; Phases of clinical research; Cohort; Gastroenterology; Surgery; Cancer; Sorafenib; Toxicity; Clinical trial; Immunotherapy; Hepatocellular carcinoma","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002895829,0.00162796,0.001417201,0.0005096222,0.0003795399,0.001297207,0.0009104706,0.001063513,0.004659987],"category_scores_gemma":[0.0009025572,0.0007533637,0.001754539,0.0003932851,0.0005927989,0.001111109,0.0005900692,0.002307849,0.00110246],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.00129908,"about_ca_system_score_gemma":0.001630643,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001009892,"about_ca_topic_score_gemma":0.00311545,"domain_scores_codex":[0.9992999,0.0003846049,0.00002854636,0.0001087999,0.00005695983,0.0001211803],"domain_scores_gemma":[0.9994276,0.0000695543,0.0001400424,0.00004701219,0.00003433691,0.0002814613],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.8493143,0.04179355,0.0161322,0.001213222,0.003779299,0.0003211177,0.0002295388,0.001686634,0.01326674,0.0003227886,0.005530942,0.06640975],"study_design_scores_gemma":[0.7683238,0.1987793,0.02383083,0.00007557932,0.001240955,0.0003394879,0.00006763673,0.0009160182,0.001105745,0.0002507405,0.005036424,0.00003340813],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9858928,0.003790033,0.000485596,0.0005756782,0.0001377209,0.004512485,0.002148605,0.0000904555,0.002366616],"genre_scores_gemma":[0.9814548,0.0020976,0.001806228,0.001738277,0.0001953751,0.00483873,0.004430666,0.00003691735,0.003401476],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.004659987,"threshold_uncertainty_score":0.01558918,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.1192102743183958,"score_gpt":0.4667918343486225,"score_spread":0.3475815600302268,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}